Noninvasive testing allows for routine risk stratification and long-term monitoring of patients with nonalcoholic fatty liver disease, offering a safer, more practical approach than biopsy.
Liver transplant might cure liver metastases in a small subset of patients with CRC but identifying which patients could benefit most remains a challenge.